{"id":"W2536315798","doi":"10.1017/cjn.2016.381","title":"PC3 - 154 Phase I/II Study of VAL-083 in Patients with Recurrent Glioblastoma","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Temozolomide; Medicine; Bevacizumab; Internal medicine; Adverse effect; Oncology; Phases of clinical research; Clinical trial; Radiation therapy; Cancer; Gastroenterology; Chemotherapy; Pharmacology; Surgery","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001136511,0.002119343,0.002114269,0.0005401724,0.0004741769,0.0008724844,0.001098002,0.001085745,0.004356721],"category_scores_gemma":[0.000588447,0.0005737651,0.001009674,0.0005494192,0.0008867668,0.0005432159,0.0003520158,0.00326082,0.001156402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001566569,"about_ca_system_score_gemma":0.003278835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005627657,"about_ca_topic_score_gemma":0.01524381,"domain_scores_codex":[0.9996954,0.0001130933,0.00001680685,0.00005427085,0.00003763727,0.00008274733],"domain_scores_gemma":[0.9996015,0.00003876328,0.00005872247,0.00003336419,0.00004066288,0.0002270072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5533434,0.1179744,0.01021834,0.001570285,0.002271083,0.0005110904,0.0005453202,0.00449015,0.1142208,0.0004701298,0.02058504,0.1738001],"study_design_scores_gemma":[0.4344276,0.5317242,0.01784587,0.0000556194,0.0005996838,0.0003366797,0.00007441668,0.001397844,0.008238411,0.000250364,0.005005355,0.00004400011],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989383,0.002208744,0.0004146587,0.0005369472,0.0001282118,0.002778402,0.001724989,0.0002483468,0.002576726],"genre_scores_gemma":[0.983443,0.002308626,0.00136412,0.001127692,0.0001247478,0.002229163,0.004726661,0.00006899681,0.00460715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005627657,"threshold_uncertainty_score":0.01457465,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02711837221309472,"score_gpt":0.2823203140877367,"score_spread":0.255201941874642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}